2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-157787
    Ginkgolic acid 2-phosphate 2281761-58-6 98%
    Ginkgolic acid 2-phosphate is a potent sphingosine 1-phosphate agonist. Ginkgolic acid 2-phosphate induces ERK phosphorylation. Ginkgolic acid 2-phosphate interactes with S1P1.
    Ginkgolic acid 2-phosphate
  • HY-157792
    Antidepressant agent 6 98%
    Antidepressant agent 6 (S-3a) is a lead compound with potent and sustained antidepressant effects. Antidepressant agent 6 (S-3a) displays high cognitive safety margin.Antidepressant agent 6 (S-3a) antagonizes M1 receptors and elevates BDNF levels, suggesting its potential as an antidepressant for further exploration.
    Antidepressant agent 6
  • HY-157806
    α-Synuclein inhibitor 12 98%
    α-Synuclein inhibitor 12 (compound 4ce) is an inhibitor of α-Syn (α-synuclein) aggregation and can be used in the study of neurological diseases.
    α-Synuclein inhibitor 12
  • HY-15780A
    Brexpiprazole hydrochloride 913612-38-1 98%
    Brexpiprazole (OPC-34712) hydrochloride, an atypical orally active antipsychotic agent, is a partial agonist of human 5-HT1A and dopamine D2L receptor with Kis of 0.12 nM and 0.3 nM, respectively. Brexpiprazole hydrochloride is also a 5-HT2A receptor antagonist with a Ki of 0.47 nM. Brexpiprazole hydrochloride also shows potent antagonist activity at human noradrenergic α1B (Ki=0.17 nM) and α2C receptors (Ki=0.59 nM).
    Brexpiprazole hydrochloride
  • HY-157931
    Anticancer agent 192 98%
    Anticancer agent 192 (compound XXI) is a steroid-based histamine H3 receptor antagonist with no affinity for muscarinics and hERG. Anticancer agent 192 is quite stable in human and rat liver microsomes. Anticancer agent 192 can improve the cognitive level and reduce the degree of addiction in rats in the in vivo addiction test.
    Anticancer agent 192
  • HY-157934
    MAO-IN-4 3023217-85-5 98%
    MAO-IN-4 (Compound 2l) is a monoamine oxidase (MAO) inhibitor, with IC50 values of 0.07 and 0.75 μM for MAO-A and MAO-B Enzymes, respectively. MAO-IN-4 can be used for the research of depression and Parkinson’s disease (PD).
    MAO-IN-4
  • HY-157935
    17β-HSD10-IN-3 2225109-18-0 98%
    17β-HSD10-IN-3 (compound 23) is a 17β-HSD10 inhibitor with the IC50 of 5.59 μM. 17β-HSD10-IN-3 shows no cell cytotoxicity toward the HEK-293 cell line up to 20 μM.
    17β-HSD10-IN-3
  • HY-157936
    GluN2B-NMDAR antagonist-2 98%
    GluN2B-NMDAR antagonist-2 (compound S-58) is a potent, selective and cross the blood-brain barrier NMDAR-GluN2B antagonist with an IC50 value of 74.01, nM. GluN2B-NMDAR antagonist-2 shows mild cytotoxicity. GluN2B-NMDAR antagonist-2 decreases the cerebral infarction rates and neurologic deficit scores. GluN2B-NMDAR antagonist-2 has the potential for the research of stroke.
    GluN2B-NMDAR antagonist-2
  • HY-15793A
    Trans (2,3)-Dihydrotetrabenazine 171598-74-6 98%
    Trans (2,3)-Dihydrotetrabenazine ((2R,3R,11bR)-rel-Dihydrotetrabenazine), a metabolite of Tetrabenazine, shows remarkable inhibition activity on vesicular monoamine transporter (VMAT2).
    Trans (2,3)-Dihydrotetrabenazine
  • HY-157955
    TAAR1 agonist 1 98%
    TAAR1 agonist 1 (compound 6E) is a potent TAAR1 agonist with a potent TAAR1-Gs/Gq dual-pathway activation property. TAAR1 agonist 1 significantly alleviates MK-801-induced schizophrenia-like cognitive phenotypes.
    TAAR1 agonist 1
  • HY-157958
    α7 nAChR Modulator-3 98%
    α7 nAChR modulator-3 (Compound 6p) is a α7 nAChR positive allosteric Modulator with a IC50 value of 1.3 μM. α7 nAChR Modulator-3 can be used to inhibit auditory gating defects in a mouse schizophrenic model.
    α7 nAChR Modulator-3
  • HY-157978
    AChE-IN-59 2957916-86-6 98%
    AChE-IN-59 (compounds 3b) is an AChE inhibitor, with an IC50 value of 0.05 μM. AChE-IN-59 can inhibit the aggregation of Aβ1-42, protect nerve cells and penetrate the blood-brain barrier well. AChE-IN-59 can be used for the research of Alzheimer's disease (AD).
    AChE-IN-59
  • HY-157981
    AChE-IN-60 98%
    AChE-IN-60 (compound 6k) is a potant acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitor with IC50s of 27 nM and 43 nM, respectively. AChE-IN-60 also inhibits monoamine oxidase (MAO)-A and MAO-B with IC50s of 353 nM and 716 nM, respectively.
    AChE-IN-60
  • HY-157982
    BChE-IN-28 98%
    BChE-IN-28 (compound 6J) is a selective butyrylcholinesterase (BChE) inhibitor with an IC50 of 8 nM and a Ki of 12.16 nM. BChE-IN-28 shows the lower inhibition against AChE, MAO-A and MAO-B.
    BChE-IN-28
  • HY-157992
    LM-021 1022282-98-9 98.27%
    LM-021 is a coumarin-chalcone derivative with anti-aggregatory, antioxidant, neuroprotective and anti-inflammatory properties which suppresses nitric oxide (NO), IL-1β, IL-6, TNF-α production, CD68 antigen (CD68) and histocompatibility-2 (MHCII) expression. LM-021 also attenuates the increase of caspase 1 activity, lactate dehydrogenase release and ROS level. LM-021 can be used for neurological research.
    LM-021
  • HY-157996
    CSF1R-IN-21 2935479-62-0 98%
    CSF1R-IN-21 (compound 7e) is a CSF-1R Inhibitor with an IC50 value of 31 nM. CSF1R-IN-21 inhibits CSF-1R auto-phosphorylation and can be used for the research of neurodegenerative diseases .
    CSF1R-IN-21
  • HY-158013
    JJC8-088 1627576-82-2 98%
    JJC8-088, a Modafinil-derived ligand, is a dopamine transporter (DAT) inhibitor with a Ki of 2.53 nM. JJC8-088 dioxalate can be to study psychostimulant use disorders.
    JJC8-088
  • HY-158014
    JJC8-089 1627576-64-0 98%
    JJC8-089 is a dopamine transporter (DAT) inhibitor that may improve motivational dysfunction and increase effortful behavior in goal-directed activities. JJC8-089 significantly reversed the low-effort effects induced by the VMAT-2 inhibitor Tetrabenazine (HY-B0590) in rats and increased the choice of high-effort fixed-ratio 5-bar presses versus food intake. .
    JJC8-089
  • HY-158030
    HDAC6-IN-37 2986486-82-0 98%
    HDAC6-IN-37 (compound W5) is an inhibitor of HDAC6 and has neuroprotective effects. HDAC6-IN-37 can restore the morphology of hippocampal neurons, reduce the expression of Aβ, Tau, and p-Tau proteins in the hippocampus of AD rats, and inhibit the formation of senile plaques and neurofibrillary tangles. Thus, HDAC6-IN-37 improves the Aβ/Cu2+-induced AD model in rats, regulates oxidative stress status, and balances neurotransmitter disorders in brain tissue.
    HDAC6-IN-37
  • HY-158051
    CIDD-0072424 1620195-03-0 98%
    CIDD-0072424 selectively inhibits Protein Kinase C-epsilon (PKCε) (Ki=54 nM). CIDD-0072424 reduces ethanol consumption and preference in a dose-dependent manner.
    CIDD-0072424
Cat. No. Product Name / Synonyms Application Reactivity